Lakewood-Amedex, Inc. Patent Portfolio Summary


Lakewood-Amedex has several families of patents in different technology sectors. However, the Company’s focus is on developing its Bisphosphocin antimicrobials for the treatment of several serious bacterial infection indications where antibiotic-resistant pathogens are particularly prevalent. The Company’s drug candidate for most of these indications is Nu-8, a new member of the Bisphosphocin class. Lakewood-Amedex has recently filed a broad patent application on this compound that if granted will provide protection until at least 2038. The Company has also recently filed a patent application on its proprietary Nu-3 gel formulation, which it intends to use in clinical trials for the treatment of chronic diabetic foot ulcers. If granted, this patent will provide protection until at least 2038.

Patent Family 1
CountryTitleApplication No.Patent No.StatusExpiry Date
PCTAntimicrobial Compounds, Compositions, and Uses ThereofPCT/US18/22068Pending
PCTAntimicrobial Compounds, Compositions, and Uses ThereofPCT/US18/22071Pending
United StatesAntimicrobial Compounds, Compositions, and Uses Thereof15/919,138Filed March 12, 2018
Patent Family 2
CountryTitleApplication No.Patent No.StatusExpiry Date
United StatesBisphophocin Gel Formulations62/518,262Filed June 12, 2017
Patent Family 3
CountryTitleApplication No.Patent No.StatusExpiry Date
AustraliaPulmonary Delivery of Protonated/Acidified Nucleic Acids2002305336AU2002305336In Force5/3/22
AustraliaAntimicrobial and Antiviral Compounds and Methods for Their Use2013276985AU2013276985In Force5/3/22
BelgiumAntimicrobial Compounds and Methods for Their Use10184218.5EP2311466In Force5/3/22
CanadaAntimicrobial Compounds and Methods for Their Use2445381CA2445381In Force5/3/22
CanadaPhosphorous Containing Antimicrobial Compounds and Methods for Their Use2827671CA2827671In Force5/3/22
DenmarkAntimicrobial Compounds and Methods for Their Use10184218.5EP2311466In Force5/3/22
European Patent ConventionAntimicrobial Compounds and Methods for Their Use2734149.4EP1389909Granted5/3/22
European Patent ConventionAntimicrobial Compounds and Methods for Their Use10184218.5EP2311466Granted5/3/22
FranceAntimicrobial Compounds and Methods for Their Use10184218.5EP2311466In Force5/3/22
FranceAntimicrobial Compounds and Methods for Their Use2734149.4EP1389909In Force5/3/22
GermanyAntimicrobial Compounds and Methods for Their Use10184218.5EP2311466In Force5/3/22
GermanyAntimicrobial Compounds and Methods for Their Use2734149.4EP1389909In Force5/3/22
GreeceAntimicrobial Compounds and Methods for Their Use10184218.5EP2311466In Force5/3/22
IrelandAntimicrobial Compounds and Methods for Their Use10184218.5EP2311466In Force5/3/22
IrelandAntimicrobial Compounds and Methods for Their Use2734149.4EP1389909In Force5/3/22
ItalyAntimicrobial Compounds and Methods for Their Use10184218.5EP2311466In Force5/3/22
JapanPulmonary Delivery of Protonated/Acidified Nucleic Acids2000-607640JP4883840In Force3/28/20
JapanAntimicrobial Compounds and Methods for Their Use2002-586732JP4347573In Force5/3/22
JapanAntimicrobial Compounds and Methods for Their Use2009-120362JP5503900In Force5/3/22
JapanAntimicrobial Compounds and Methods for Their Use2013-210031JP5883838In Force5/3/22
JapanProtonated/Acidified Nucleic Acids and Methods of Use2015-219286 JP6097372In Force5/3/22
LiechtensteinAntimicrobial Compounds and Methods for Their Use10184218.5EP2311466In Force5/3/22
NetherlandsAntimicrobial Compounds and Methods for Their Use10184218.5EP2311466In Force5/3/22
NetherlandsAntimicrobial Compounds and Methods for Their Use2734149.4EP1389909In Force5/3/22
PortugalAntimicrobial Compounds and Methods for Their Use10184218.5EP2311466In Force5/3/22
SpainAntimicrobial Compounds and Methods for Their Use10184218.5EP2311466In Force5/3/22
SwedenAntimicrobial Compounds and Methods for Their Use10184218.5EP2311466In Force5/3/22
SwedenAntimicrobial Compounds and Methods for Their Use2734149.4EP1389909In Force5/3/22
SwitzerlandAntimicrobial Compounds and Methods for Their Use10184218.5EP2311466In Force5/3/22
SwitzerlandAntimicrobial Compounds and Methods for Their Use2734149.4EP1389909In Force5/3/22
United KingdomAntimicrobial Compounds and Methods for Their Use10184218.5EP2311466In Force5/3/22
United KingdomAntimicrobial Compounds and Methods for Their Use2734149.4EP1389909In Force5/3/22
United StatesAntimicrobial and Antiviral Compounds and Methods for Their Use11/552951US7868162In Force 06/03/21[1]
[1] This patent is subject to 886 days of Patent Term Adjustment.
Patent Family 4
CountryTitleApplication No.Patent No.StatusExpiry Date
ChinaOligonucleotide-Containing Pharmacological Compositions and Their Use2813802.3CN100344646In Force7/10/22
European Patent ConventionOligonucleotide-Containing Pharmacological Compositions and Their Use2749875.7EP1414841Granted7/10/22
FranceOligonucleotide-Containing Pharmacological Compositions and Their Use2749875.7EP1414841In Force7/10/22
GermanyOligonucleotide-Containing Pharmacological Compositions and Their Use2749875.7EP1414841In Force7/10/22
IrelandOligonucleotide-Containing Pharmacological Compositions and Their Use2749875.7EP1414841In Force7/10/22
IsraelOligonucleotide-Containing Pharmacological Compositions and Their Use159722IL159722In Force7/10/22
JapanOligonucleotide-Containing Pharmacological Compositions and Their Use2003-512248JP4999255In Force7/10/22
United KingdomOligonucleotide-Containing Pharmacological Compositions and Their Use2749875.7EP1414841In Force7/10/22
United StatesOligonucleotide-Containing Pharmacological Compositions and Their Use11/673486US8916529In Force10/29/24[2]
United StatesOligonucleotide-Containing Pharmacological Compositions and Their Use11/673508US8188259In Force01/19/23[3]
United StatesOligonucleotide-Containing Pharmacological Compositions and Their Use11/673509US8183361In Force02/23/23[4]
United StatesOligonucleotide-Containing Pharmacological Compositions and Their Use14/534901US9567584In Force7/10/22
[2] This patent is subject to 842 days of Patent Term Adjustment.
[3] This patent is subject to 193 days of Patent Term Adjustment.
[4] This patent is subject to 228 days of Patent Term Adjustment.
Patent Family 5
CountryTitleApplication No.Patent No.StatusExpiry Date
AustraliaCompositions and Methods for the Treatment of Muscle Wasting2006345724AU2006345724In Force6/30/26
CanadaCompositions and Methods for the Treatment of Muscle Wasting2558160CA2558160In Force6/30/26
ChinaCompositions and Methods for the Treatment of Muscle Wasting200510077730.2CN100393320In Force6/24/25
United KingdomCompositions and Methods for the Treatment of Muscle Wasting616790.2GB2441581In Force6/30/26
United StatesCompositions and Methods for the Treatment of Muscle Wasting11/479112US8097596In Force08/11/29[5]
[5] This patent is subject to 1138 days of Patent Term Adjustment.
Patent Family 6
CountryTitleApplication No.Patent No.StatusExpiry Date
ChinaCompositions and Methods for the Treatment of Influenza Infection200610000900.1CN100562342In Force1/17/26
United StatesCompositions and Methods for the Treatment of Influenza Infection11/458378US9574243In Force09/21/30[6]
United StatesCompositions and Methods for the Treatment of Influenza Infection15/400,797Pending
[6] This patent is subject to 1526 days of Patent Term Adjustment.